[Clinical pharmacology and therapeutic aspects in certain degenerative neurological diseases].
The knowledge in the pathophysiology of neurodegenerative disorders, and their classification has been dramatically improved by the progresses in genetics and molecular biology. Such a progress has not yet been observed in therapeutics but sustained symptomatic results may occur in the treatment of Parkinson's disease and to a lesser extent in Alzheimer's disease. More recently, other therapeutic approaches were used in trials with neuroprotective drugs with some encouraging results.
Maloteaux
J M
JM
D000544:Alzheimer Disease / Q000188:drug therapy*; D000690:Amyotrophic Lateral Sclerosis / Q000188:drug therapy* / Q000235:genetics; D000978:Antiparkinson Agents / Q000627:therapeutic use; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use; D006801:Humans; D018696:Neuroprotective Agents / Q000494:pharmacology / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000188:drug therapy*; D019782:Riluzole / Q000627:therapeutic use; D012642:Selegiline / Q000627:therapeutic use; D013619:Tacrine / Q000627:therapeutic use
D000978:Antiparkinson Agents; D002800:Cholinesterase Inhibitors; D018696:Neuroprotective Agents; D012642:Selegiline; D013619:Tacrine; D019782:Riluzole
Pharmacologie clinique et aspects thérapeutiques dans certaines maladies neurologiques dégénératives.